Mabylon AG Starts Phase I Trial For Peanut Allergy Treatment
11 Dec 2025 //
PHARMIWEB
Mabylon AG Secures CHF 30M For MY006 Peanut Allergy Program
12 Aug 2025 //
PHARMAWEB
SciNeuro and Mabylon Collaborate to develop therapy for Neurological Diseases
26 Oct 2021 //
BUSINESSWIRE

Market Place
Sourcing Support